Share on StockTwits

Protalix BioTherapeutics (NYSE:PLX) was the target of a large increase in short interest in July. As of July 31st, there was short interest totalling 5,921,103 shares, an increase of 6.7% from the July 15th total of 5,548,739 shares, ARN reports. Currently, 8.2% of the company’s stock are short sold. Based on an average trading volume of 377,056 shares, the days-to-cover ratio is presently 15.7 days.

Several analysts have recently commented on the stock. Analysts at Jefferies Group reiterated a “hold” rating on shares of Protalix BioTherapeutics in a research note on Monday. They now have a $3.50 price target on the stock, down previously from $4.25. Analysts at JPMorgan Chase & Co. cut their price target on shares of Protalix BioTherapeutics from $8.00 to $7.00 in a research note on Tuesday, May 13th. They now have an “overweight” rating on the stock.

Shares of Protalix BioTherapeutics (NYSE:PLX) traded down 4.23% during mid-day trading on Monday, hitting $2.94. 348,513 shares of the company’s stock traded hands. Protalix BioTherapeutics has a one year low of $2.91 and a one year high of $5.60. The stock’s 50-day moving average is $3.38 and its 200-day moving average is $4.11. The company’s market cap is $272.5 million.

Protalix BioTherapeutics (NYSE:PLX) last posted its quarterly earnings results on Thursday, May 22nd. The company reported ($0.08) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.07) by $0.01. On average, analysts predict that Protalix BioTherapeutics will post $-0.24 earnings per share for the current fiscal year.

Protalix BioTherapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx.

Receive News & Ratings for Protalix BioTherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.